Please login to the form below

Not currently logged in

Merck to launch Tredaptive internationally

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009.

Tredaptive (also known as Cordaptive) is a therapy for patients with mixed dyslipidemia and primary hypercholesterolemia. It has been licensed in the EU for use in combination with statins or as a monotherapy when statins are inappropriate.

It is approved for use in 39 countries outside of the US. The FDA refused to approve the drug for use in the US until more supporting evidence was available.

"Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care," said Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular, Merck Research Laboratories.

19th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....